Aquinox Axes Half its Workforce After Phase III Failure of Lead Drug Rospitor

Two weeks after acknowledging the failure of its lead drug candidate Rospitor (AQX-1125) in a Phase III trial in patients with interstitial cystitis/bladder pain syndrome (IC/BPS), Aquinox Pharmaceuticals has eliminated half its workforce—30 employees—and shut down its U.S. offices in San Bruno, CA.The Vancouver, BC, drug developer said the layoffs and office shutdown were part of a restructuring plan designed to reduce operating costs and better align the Company’s workforce w